Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator (uPA) is a diagnostic marker for breast and prostate cancers recommended by American Society for Clinical Oncology and German Breast Cancer Society.
|
30707839 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa).
|
31797075 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overexpression of urokinase-type plasminogen activator receptors (uPARs) represents an established biomarker for aggressiveness in most common malignant diseases, including breast cancer (BC), prostate cancer (PC), and urinary bladder cancer (UBC), and is therefore an important target for new cancer therapeutic and diagnostic strategies.
|
27609788 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MS-HRM analysis revealed aberrant methylation of uPA promoter in LNCaP cells, but not in PrEC, DU-145 and PC-3 cells, as well as in normal and prostate cancer tissue samples.
|
23541763 |
2013 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts.
|
22293856 |
2012 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that PKD2 and PKD3 coordinate to promote prostate cancer cell invasion through p65 NF-κB- and HDAC1-mediated expression and activation of uPA.
|
22797919 |
2012 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
OSM and IL-6 increase u-PA and VEGF in DU-145 cells but not in PPEC and possibly, by promoting matrix degradation and angiogenesis, could play a role in the pathogenesis of prostate cancer.
|
21965736 |
2011 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer (PC-3) cells have highly invasive capacity and they express uPA and uPAR gene.
|
21308698 |
2011 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These actions include increased secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in prostate cancer cell invasion.
|
19001380 |
2009 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the functional role of PC cell-associated uPA in intraosseous tumor growth and bone matrix degradation.
|
18472961 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator (uPA) is thought to be critically involved in the metastatic phenotype of prostate cancer.
|
18225541 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that inhibition of NF-kappaB DNA binding activity by B-DIM contributes to the regulated bioavailability of VEGF by MMP-9 and uPA and, in turn, inhibits invasion and angiogenesis, which could be mechanistically linked with the antitumor activity of B-DIM as observed previously by our laboratory in a prostate cancer animal model.
|
17409440 |
2007 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Matrigel invasion assay was used to study the influence of uPA inhibitors on the invasive potential of prostate cancer cell lines.
|
16430655 |
2006 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Matrigel invasion assays with two specific uPA inhibitors, B428 and p-aminobenzamidine, showed that invasion of a prostate cancer cell line containing uPA gene amplification was inhibited by these small-molecule uPA inhibitors, while invasion of prostate cell lines without uPA gene amplification were not.
|
16430655 |
2006 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most commonly implicated protease in these processes is urokinase type plasminogen activator (uPA), which is known to be expressed in a number of malignancies including breast and prostate cancer and is directly associated with the higher invasive and metastatic potential of malignancies.
|
16305345 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
|
17192053 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
|
15023541 |
2004 |
Malignant neoplasm of prostate
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Collectively these studies have demonstrated that DNA methylation is the underlying molecular mechanism responsible for uPA gene silencing in normal and early stages of prostate cancer, which has a direct effect on tumor cell invasion and growth in vitro and in vivo.
|
12773490 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Amplification and overexpression of urokinase type plasminogen-activator in prostate cancer has previously been reported.
|
12004003 |
2002 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of uPA has been reported in various malignancies including prostate cancer.
|
11454671 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Collectively, these results show that MAPK pathways ERK, JNK/SAPK, and P38-MAPK represent a significant component in the regulation of u-PA expression in human CaP.
|
11676474 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regulation of u-PA gene expression in human prostate cancer.
|
11745419 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Matrigel invasion assay showed that prostate cancer cell line PC-3, containing amplification of the uPA gene, was more sensitive to the urokinase inhibitor, amiloride, than DU145 or LNCaP cell lines, which do not have the amplification.
|
11454671 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although uPA production is regulated by various growth factors and cytokines, the role of sex steroids (androgens) in regulating uPA gene expression in prostate cancer is poorly understood.
|
10465276 |
1999 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined the expression of uPA in the prostate cancer cell lines LNCaP, DU-145 and PC-3.
|
9751264 |
1998 |